Tutorials
Oncternal Therapeutics Inc logo

Oncternal Therapeutics Inc

$ 1.16 +0.03 (+2.65%) 08:08 PM EST
P/E:
At Loss
P/B:
0.72
Market Cap:
$ 61.73M
Enterprise V:
$ -17.02M
Volume:
1.12M
Avg Vol (2M):
622.94K
Also Trade In:
Volume:
1.12M
Market Cap $:
61.73M
PE Ratio:
At Loss
Avg Vol (2-Month):
622.94K
Enterprise Value $:
-17.02M
PB Ratio:
0.72
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Oncternal Therapeutics Inc
NAICS : 325412 SIC : 2834
12230 El Camino Real, Suite 300, San Diego, CA, USA, 92130
Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Name Current Vs Industry Vs History
Cash-To-Debt 2650.29
Equity-to-Asset 0.94
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -3.39
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 69.66
9-Day RSI 61.43
14-Day RSI 56.18
6-1 Month Momentum % -42.78
12-1 Month Momentum % -70.71

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 16.07
Quick Ratio 16.07
Cash Ratio 15.52

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -143.2

Financials (Next Earnings Date:2022-11-04 Est.)

ONCT's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ONCT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.71
Beta 1.48
Volatility % 100.11
14-Day RSI 56.18
14-Day ATR ($) 0.081595
20-Day SMA ($) 1.094
12-1 Month Momentum % -70.71
52-Week Range ($) 0.6902 - 4.63
Shares Outstanding (Mil) 53.21

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Oncternal Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More